QuidelOrtho [QDEL] vs Exact Sciences [EXAS] Detailed Stock Comparison
QuidelOrtho
NASDAQ
Loading...
Exact Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: QuidelOrtho wins in 12 metrics, Exact Sciences wins in 6 metrics, with 0 ties. QuidelOrtho appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | QuidelOrtho | Exact Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.75 | -8.54 | Exact Sciences |
| Price-to-Book Ratio | 0.51 | 3.76 | QuidelOrtho |
| Debt-to-Equity Ratio | 90.01 | 105.93 | QuidelOrtho |
| PEG Ratio | 8.61 | -140.47 | Exact Sciences |
| EV/EBITDA | 7.36 | 282.53 | QuidelOrtho |
| Profit Margin (TTM) | -12.97% | -36.06% | QuidelOrtho |
| Operating Margin (TTM) | 7.03% | -11.53% | QuidelOrtho |
| EBITDA Margin (TTM) | 7.03% | N/A | N/A |
| Return on Equity | -11.38% | -36.89% | QuidelOrtho |
| Return on Assets (TTM) | 1.12% | -1.83% | QuidelOrtho |
| Free Cash Flow (TTM) | $-112.10M | $74.55M | Exact Sciences |
| 1-Year Return | -45.70% | -16.72% | Exact Sciences |
| Price-to-Sales Ratio (TTM) | 0.56 | 3.19 | QuidelOrtho |
| Enterprise Value | $4.13B | $10.76B | Exact Sciences |
| EV/Revenue Ratio | 1.49 | 3.81 | QuidelOrtho |
| Gross Profit Margin (TTM) | 49.55% | 70.82% | Exact Sciences |
| Revenue per Share (TTM) | $41 | $15 | QuidelOrtho |
| Earnings per Share (Diluted) | $-5.23 | $-5.53 | QuidelOrtho |
| Beta (Stock Volatility) | 0.07 | 0.95 | QuidelOrtho |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
QuidelOrtho vs Exact Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| QuidelOrtho | -0.91% | -16.72% | -23.43% | -18.19% | -46.37% | -49.36% |
| Exact Sciences | 1.73% | -1.51% | -12.53% | 1.27% | -13.54% | -16.11% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| QuidelOrtho | -45.70% | -75.26% | -91.64% | 10.67% | 77.93% | 220.82% |
| Exact Sciences | -16.72% | 1.51% | -44.91% | 108.47% | 1,021.13% | 1,825.81% |
Performance & Financial Health Analysis: QuidelOrtho vs Exact Sciences
| Metric | QDEL | EXAS |
|---|---|---|
| Market Information | ||
| Market Cap | $1.54B | $9.01B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 1,569,608 | 2,310,910 |
| 90 Day Avg. Volume | 1,698,839 | 2,629,947 |
| Last Close | $22.81 | $47.76 |
| 52 Week Range | $22.05 - $49.45 | $39.97 - $72.83 |
| % from 52W High | -53.87% | -34.42% |
| All-Time High | $306.72 (Aug 03, 2020) | $159.54 (Jan 25, 2021) |
| % from All-Time High | -92.56% | -70.06% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.03% | 0.11% |
| Quarterly Earnings Growth | -0.03% | 0.11% |
| Financial Health | ||
| Profit Margin (TTM) | -0.13% | -0.36% |
| Operating Margin (TTM) | 0.07% | -0.12% |
| Return on Equity (TTM) | -0.11% | -0.37% |
| Debt to Equity (MRQ) | 90.01 | 105.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $44.40 | $12.71 |
| Cash per Share (MRQ) | $1.89 | $4.17 |
| Operating Cash Flow (TTM) | $149.30M | $323.66M |
| Levered Free Cash Flow (TTM) | $297.44M | $163.08M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: QuidelOrtho vs Exact Sciences
| Metric | QDEL | EXAS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.75 | -8.54 |
| Forward P/E | 8.61 | -140.47 |
| PEG Ratio | 8.61 | -140.47 |
| Price to Sales (TTM) | 0.56 | 3.19 |
| Price to Book (MRQ) | 0.51 | 3.76 |
| Market Capitalization | ||
| Market Capitalization | $1.54B | $9.01B |
| Enterprise Value | $4.13B | $10.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.49 | 3.81 |
| Enterprise to EBITDA | 7.36 | 282.53 |
| Risk & Other Metrics | ||
| Beta | 0.07 | 0.95 |
| Book Value per Share (MRQ) | $44.40 | $12.71 |
Financial Statements Comparison: QuidelOrtho vs Exact Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QDEL | EXAS |
|---|---|---|
| Revenue/Sales | $692.80M | $706.79M |
| Cost of Goods Sold | $349.50M | $206.24M |
| Gross Profit | $343.30M | $500.55M |
| Research & Development | $53.20M | $105.31M |
| Operating Income (EBIT) | $48.70M | $-89.76M |
| EBITDA | $154.20M | $-36.86M |
| Pre-Tax Income | $-8.80M | $-100.99M |
| Income Tax | $3.90M | $224,000 |
| Net Income (Profit) | $-12.70M | $-101.22M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QDEL | EXAS |
|---|---|---|
| Cash & Equivalents | $127.10M | $347.13M |
| Total Current Assets | $1.26B | $1.37B |
| Total Current Liabilities | $1.05B | $502.47M |
| Long-Term Debt | $2.27B | $2.49B |
| Total Shareholders Equity | $3.00B | $2.40B |
| Retained Earnings | $123.10M | $-4.60B |
| Property, Plant & Equipment | $2.35B | $126.66M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QDEL | EXAS |
|---|---|---|
| Operating Cash Flow | $41.90M | $-36.98M |
| Capital Expenditures | $-56.20M | $-31.17M |
| Free Cash Flow | $9.40M | $-365,000 |
| Debt Repayment | $-36.00M | $-249.17M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | QDEL | EXAS |
|---|---|---|
| Shares Short | 6.25M | 7.47M |
| Short Ratio | 3.68 | 2.55 |
| Short % of Float | 0.15% | 0.05% |
| Average Daily Volume (10 Day) | 1,569,608 | 2,310,910 |
| Average Daily Volume (90 Day) | 1,698,839 | 2,629,947 |
| Shares Outstanding | 67.26M | 185.62M |
| Float Shares | 62.35M | 186.79M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.13% | 0.99% |
Dividend Analysis & Yield Comparison: QuidelOrtho vs Exact Sciences
| Metric | QDEL | EXAS |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |